• Logo
  • SBMUJournals

Assessment of antibiotic resistance pattern in Acinetobacter bumannii carrying bla oxA type genes isolated from hospitalized patients

Hossein Goudarzi, Masoumeh Douraghi, Zohreh Ghalavand, Mehdi Goudarzi
839

Views

PDF

Abstract

Abstract

Please cite this article as: Goudarzi H, Douraghi M, Ghalavand Z, Goudarzi M. Assessment of antibiotic resistance pattern in Acinetobacter baumannii carrying bla oxA type genes isolated from hospitalized patients. Novel Biomed 2013;1(2):54-61.

Introduction: Acinetobacter baumannii is a Gram-negative coccobacillus and one of the most opportunistic pathogens responsible for serious infections in hospitalized patients.

Methods: During a 12 month study, 221 clinical isolates and 22 environmental Acinetobacter baumannii isolates were collected. In vitro susceptibility of Acinetobacter baumannii isolates to 13 antimicrobial agents amikacin; cefepime; ceftazidime; ciprofloxacin; meropenem; piperacillin/tazobactam; sulfamethoxazole/ trimethoprim; imipenem; tigecycline; colistin; gentamycin; ceftriaxone; levofloxacin was performed by the disk diffusion method and Minimum Inhibitory Concentration(MICs) of imipenem; levofloxacin and cefepime.was done by the E-test according to Clinical and Laboratory Standards Institute (CLSI) criteria. blaOXA-23, blaOXA-24, blaOXA-58, blaOXA-51genes were detected by polymerase chain reaction and sequencing.

Results: The result of antimicrobial susceptibility test of clinical isolates by the disk diffusion method revealed that that all strains of Acinetobacter baumannii were resistant to piperacillin/tazobactam. The rates of resistance to the majority of antibiotics tested varied between 69% and 100 %, with the exception of tigecycline and colistin. Of 221 isolates tested 99(44.8%) were XDR. All strains carry a blaOXA-51-like gene. blaOXA-23gene was the most prevalence among blaOXA-types.

Conclusion: colistin and tigecycline can be effective drugs for treatment of Acinetobacter baumannii infections. Continuous Surveillance for Acinetobacter baumannii multidrug-resistant strains is necessary to prevent the further spread of resistant isolates.


References

Houang ET, Chu YW, Leung CM, Chu KY, Berlau J, Ng KC, Cheng AF. Epidemiology and infection control implications of Acinetobacter spp. in Hong Kong. J Clin Microbiol 2001;39(1):228-34.

Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents 2012 ;39(2):105-14.

Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42: 692-9.

Kusradze Ia, Diene SM, Goderdzishvili M, Rolain JM. Molecular detection of OXA carbapenemase genes in multidrug-resistant Acinetobacter baumannii isolates from Iraq and Georgia. Int J Antimicrob Agents 2011;38(2):164-8.

Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG,et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18(3):268-81.

Zarrilli R, Giannouli M, Tomasone F, Triassi M, Tsakris A. Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features of an emerging problem in health care facilities. J Infect Dev Ctries 2009;3(5):335-41.

Poirel L, Nordmann P. Carbapenemresistance in Acinetobacter baumannii:mechanisms and epidemiology. Clin Microbiol Infect 2006; 12: 826–36.

Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008;21(3):538-82.

Poirel L, Mansour W, Bouallegue O, Nordmann P. Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97. Antimicrob Agents Chemother 2008;52(5):1613-7.

Carretto E, Barbarini D, Dijkshoorn L, van der Reijden TJ, Brisse S, Passet V, et al. Widespread carbapenem resistant Acinetobacter baumannii clones in Italian hospitals revealed by a multicenter study. Infect Genet Evol 2011;11(6):1319-26.

Brown S, Young HK, Amyes SG. Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina. J Clin Microbiol Infect Dis 2005;11(1):15-23.

Zarrilli R, Crispino M, Bagattini M, Barretta E, Di Popolo A, Triassi M, et al. Molecular epidemiology of sequential outbreaks of Acinetobacter baumannii in an intensive care unit shows the emergence of carbapenem resistance. J Clin Microbiol 2004;42(3):946-53.

Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. CLSI document M100-S17. Wayne, PA: CLSI; 2011.

Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, Livermore DM, et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett 2006;258(1):72-7.

Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 2006;27(4):351-3.

Feizabadi MM, Fathollahzadeh B, Taherikalani M, Rasoolinejad M, Sadeghifard N, Aligholi M, et al. Antimicrobial susceptibility patterns and distribution of blaOXA genes among Acinetobacter spp. Isolated from patients at Tehran hospitals. Jpn J Infect Dis 2008;61(4):274-8.

Reguero MT, Medina OE, Hernández MA, Flórez DV, Valenzuela EM, Mantilla JR. Antibiotic resistance patterns of Acinetobacter calcoaceticus-A. baumannii complex species from Colombian hospitals. Enferm Infecc Microbiol Clin 2013;31(3):142-6.

Yan ZQ, Shen DX, Cao JR, Chen R, Wei X, Liu LP, et al. Susceptibility patterns and molecular epidemiology of multidrug-resistant Acinetobacter baumannii strains from three military hospitals in China. Int J Antimicrob Agents 2010;35(3):269-73.

Aimsaad L, Diraphat P, Utrarachkij F, Thunyaharn S, Samakoses R, Siripanichgon K. Epidemiological characteristics of Acinetobacter baumannii infections at Phramongkutklao Hospital. J Med Assoc Thai. 2009;92 Suppl 7:164-72.

Vahdani P, Yaghoubi T, Aminzadeh Z. Hospital acquired antibiotic-resistant Acinetobacter baumannii infections in a 400-bed hospital in Tehran, Iran. Int J Prev Med. 2011;2(3):127-30.

Lolans K, Rice TW, Munoz-Price LS, Quinn JP. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 2006;50(9):2941-5.

Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002;8(6):321-31.

Ben RJ, Yang MC, Hsueh JC, Shiang JC, Chien ST. Molecular characterisation of multiple drug-resistant Acinetobacter baumannii isolates in southern Taiwan. Int J Antimicrob Agents 2011;38(5):403-8.

Poirel L, Le Thomas I, Naas T, Karim A, Nordmann P. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum beta-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrob Agents Chemother 2000;44(3):622-32.

Boroumand MA, Akhyani H, Sheikhvatan M, Hekmat Yazdi S, Saboorian R, Hashemi SH. Evaluation of Antimicrobial Resistance of Acinetobacter baumannii to Imipenem, Ciporofloxacin and Ceftazidime using E Test. Iranian Journal of Public Health 2009; 38(2):130-133.

Shali AK. Identification of Multidrug-Resistant Genes in Acinetobacter baumannii in Sulaimani City-Kurdistan Regional Government of Iraq. Asian Journal of Medical Sciences 2012;4(5):179-183.

Amazian K, Fendri C, Missoum MF, Bouzouaia N, Rahal K, Savey A, et al. Multicenter pilot survey of resistant bacteria in the Mediterranean area. Eur J Clin Microbiol Infect Dis 2006;25(5):340-3.

Ramoul A, Hammami S, Dekhil M, Aimiri S, Slim A, Boutiba-Ben Boubaker I. Phenotypic and genotypic characterization of clinical multidrug resistant Acinetobacter baumannii from Algerian intensive care units. Afr J Microbiol Res 2013;7(10):868-74.

Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51(10):3471-84.

Dhabaan GN, Hamimah H, Shorman MA. Emergence of extensive drug-resistant Acinetobacter baumannii in North of Jordan. Afric J Microbiol Res 2011;5(9):1070-5.

Héritier C, Poirel L, Nordmann P. Cephalosporinase over-expression resulting from insertion of ISAba1 in Acinetobacter baumannii. Clin Microbiol Infect 2006;12(2):123-30.




DOI: https://doi.org/10.22037/nbm.v1i2.5093